Conversion of CellCept to Myfortic: A Prospective Study in Liver Transplant Recipients

Summary

The objective of this study is to determine the tolerability and safety of Myfortic in liver transplant patients. Patients receiving CellCept who have GI side effects will have CellCept discontinued and changed to Myfortic (Myfortic is a new drug similar to CellCept, except it is enteric-coated). Our hypothesis is that Myfortic has less GI side effects and will, therefore, be tolerated better than CellCept and also that Myfortic will have a comparable effectiveness to CellCept.

Timeline

Start

2006-11

Primary completion

2008-11

Completion

2008-11

Drugs

Indications